Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.

Chongchong ZhouJingxuan WeiKai XuYing-Tao LinLingli ZhangXin Li

Published in: Risk management and healthcare policy (2023)

Tislelizumab plus chemotherapy as the first treatment for patients with advanced or metastatic ESCC may be a cost-effective option compared to chemotherapy alone at 3 times Chinese GDP per capita.

Keyphrases

locally advanced
squamous cell carcinoma
small cell lung cancer
rectal cancer
radiation therapy
combination therapy